T and NK cells: Two sides of tumor immunoevasion

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Fruci, Doriana ^a   Monaco, Elisa L ^b   Cifaldi, Loredana ^a   Locatelli, Franco ^a,c   Tremante, Elisa ^b   Benevolo, Maria ^b   Giacomini, Patrizio ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HLA E ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A; PROSTAGLANDIN E2;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MELANOMA; NATURAL KILLER CELL; NOTE; OVARY CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR ESCAPE;

ADAPTIVE IMMUNITY; ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84873158034     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-30     Document Type: Note

References (20)

1. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72:1407-1415. 10.1158/0008-5472.CAN-11-2544, 22258454.
2. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions-letter. Cancer Res 2012, 72:5428-5429. 10.1158/0008-5472.CAN-12-1181, 23047870.
3. Pietra G, Vitale M, Manzini C, Balsamo M, Moretta L, Mingari MC. Melanoma cells inhibit NK cell functions-response. Cancer Res 2012, 72:5430.
4. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother 2011, 60:1061-1074. 10.1007/s00262-011-1053-z, 3508514, 21656157.
5. Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM. CD8 T cell help for innate antitumor immunity. J Immunol 2007, 179:6651-6662.
6. Shanker A, Buferne M, Schmitt-Verhulst AM. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 2010, 129:41-54. 10.1111/j.1365-2567.2009.03150.x, 2807485, 20050329.
7. Fruci D, Benevolo M, Cifaldi L, Lorenzi S, Lo Monaco E, Tremante E, Giacomini P. Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. Curr Oncol 2012, 19:39-41. 3267590, 22328841.
8. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011, 17:6985-6991. 10.1158/1078-0432.CCR-11-1331, 22068654.
9. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386. 10.1093/carcin/bgp014, 19136477.
10. Mandapathil M, Whiteside TL. Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E(2) cooperation. Expert Opin Biol Ther 2011, 11:1203-1214. 10.1517/14712598.2011.581225, 3149765, 21702720.
11. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012, 188:21-28. 10.4049/jimmunol.1101029, 3249979, 22187483.
12. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. J Exp Med 2002, 196:459-468. 10.1084/jem.20020121, 2196046, 12186838.
13. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006, 12:1144-1151. 10.1158/1078-0432.CCR-05-1966, 16489067.
14. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, Pan ZZ, Wan DS, Zeng YX, Zhang XS. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 2009, 7:71. 10.1186/1479-5876-7-71, 2736158, 19695096.
15. Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P. Human Leukocyte Antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 2011, 13:822-830. 3182274, 21969815.
16. Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M, Giacomini P. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011, 9:184. 10.1186/1479-5876-9-184, 3219584, 22032294.
17. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 2009, 182:4572-4580. 10.4049/jimmunol.0803900, 2938179, 19342631.
18. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713. 10.1038/nature03847, 16079848.
19. Cifaldi L, Lo Monaco E, Forloni M, Giorda E, Lorenzi S, Petrini S, Tremante E, Pende D, Locatelli F, Giacomini P, Fruci D. Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res 2011, 71:1597-1606. 10.1158/0008-5472.CAN-10-3326, 21252114.
20. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G. Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 2009, 9:1043-1055. 10.1517/14712590903085109, 19591629.